SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint
SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.
How this was made

The 30-second read
Why it matters
The trial’s OS primary endpoint success and the company’s stated intent to pursue an accelerated filing pathway for a first-half 2027 BLA are the core catalysts for near-term repricing and positioning.
Market read
Traders can act on a fresh pivotal clinical readout (OS) and a concrete regulatory filing timeline plan, driving immediate momentum and options/volatility dynamics.
What to watch
Key next risks are FDA feedback on the accelerated pathway, BLA dossier completeness, and whether confirmatory evidence requirements could extend timelines or dilute the accelerated benefit.
Background
REGAL is a Phase 3 maintenance monotherapy study in AML patients in second or later complete remission (or CRp2+) who are ineligible for or unable to undergo allogeneic stem cell transplantation.
Ticker impact
SELLAS shares surge after Phase 3 REGAL trial met its overall survival primary endpoint for Galinpepimut-S, cutting death risk by 41% vs BAT.
Likely further upside pressure as traders price in accelerated BLA timing and higher odds of regulatory acceptance, with volatility elevated given trial-to-approval uncertainty.
The article reports a primary endpoint win with OS medians and a stated plan to pursue an accelerated filing pathway, which are direct, decision-relevant catalysts for biotech valuation.
Market effects
Reinforces appetite for immuno-oncology vaccine platforms and can lift sentiment for small-cap oncology biotech trial-readouts.
Primarily US small-cap biotech flow impact; limited direct spillover beyond healthcare growth factors.
Modest global read-through for clinical-trial success expectations in AML maintenance immunotherapy.
Counterpoint
A Phase 3 OS win may already be partially anticipated by the market, and the stock’s magnitude of move can invite profit-taking before FDA interaction details are known.
Key entities
- companySELLAS Life Sciences Group, Inc.
Sponsor of the REGAL Phase 3 trial for Galinpepimut-S (GPS) in AML maintenance immunotherapy.
- drug_candidateGalinpepimut-S (GPS)
Immunotherapeutic cancer vaccine evaluated as maintenance monotherapy in REGAL.
- regulatorFDA
Regulatory agency SELLAS plans to meet with to discuss an accelerated filing pathway and BLA submission timing.
